Acrivon Therapeutics Presents Preclinical Data on CHK1/2 Inhibitor ACR-368 and WEE1/PKMYT1 Inhibitor ACR-2316 at AACR Annual Meeting.

Acrivon Therapeutics will present preclinical data at the 2026 AACR Annual Meeting showing synergy between ACR-368, a CHK1/2 inhibitor, and Topoisomerase 1 inhibitors in antibody-drug conjugates. ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated complete tumor regression in combination with anti-PD-L1 checkpoint inhibition in immunocompetent mouse models. These findings support Acrivon's approach to identifying therapeutic candidates and combinations with clinical potential.